Who
Avraham Gabay
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Oramed Pharmaceuticals; Director, Lifeward.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $752K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 17 Jun 2019
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $90K20,000 at $4.51 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —209,291 | filing |
| 24 Sep 2026filed 25 Sep 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —209,291 | filing |
| 20 Aug 2026filed 24 Aug 2026 | LFWD LifewardMedical Devices | SEC FORM 4 Code A | —13,643 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | LFWD LifewardMedical Devices | SEC FORM 4 Code A | —13,643 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $331K73,360 at $4.51 | filing |
| 1 Jul 2026filed 2 Jul 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $331K73,360 at $4.51 | filing |
| 17 Mar 2026filed 18 Mar 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —95,889 at $0.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —95,889 at $0.00 | filing |
| 22 Jan 2026filed 29 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —19,000 at $0.00 | filing |
| 22 Jan 2026filed 29 Jan 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,000 at $0.00 | filing |
| 22 Jan 2026filed 29 Jan 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,000 at $0.00 | filing |
| 22 Jan 2026filed 29 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —19,000 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —81,216 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —81,216 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 11 Feb 2025filed 11 Feb 2025 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
News
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)ORMP · tickerreport.com · 11 Oct 2026Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Oramed Pharmaceuticals (NASDAQ:ORMP)ORMP · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Avraham Gabay; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.